ABVC BioPharma vs Clene
ABVC and CLNN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABVC and CLNN compare
Clene is the larger company, worth 2.0 times as much as ABVC BioPharma ($50.4M against $25.6M).
ABVC BioPharma scores higher on the StockData Score (4 against 1 for Clene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABVC | CLNN |
|---|---|---|
| Size and price | ||
| Market cap | $25.6M | $50.4M |
| Share price | $0.960 | $3.92 |
| Change, 1 year | −66.8% | −58.3% |
| Change, 5 years | −97.1% | −96.1% |
| Beta (5Y) | 1.07 | 0.79 |
| Employees | 19 | 79 |
| StockData Score | ||
| Total score | 4 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 212× |
| P/B | 2.0× | – |
| Growth | ||
| Revenue growth (TTM) | – | 11.2% |
| Revenue growth, 5Y average | −9.3% | −0.59% (better) |
| Profitability | ||
| Gross margin | – | 68.5% |
| Operating margin | – | −8929% |
| Net margin | – | −11271% |
| Return on equity | −31.2% | – |
| Return on invested capital | −35.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −34.5× | −7.3× (better) |
| Current ratio | 0.20 | 0.85 (better) |
| Altman Z-score | −4.82 (better) | −23.07 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.1% | 24.8% |
| Held by insiders | 0.49% | 45.9% |
| Insider net buying, 12 months | – | −$5.6M |
| Short interest, % of float | – | 6.0% |
Go deeper
- ABVC stock overview
- ABVC income statement
- ABVC valuation and score
- CLNN stock overview
- CLNN income statement
- CLNN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.